Tafluposide
Alternative Names: F 11782Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Pierre Fabre
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in France (IV)
- 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2007) added to the adverse events and Cancer therapeutic trials sections
- 06 Aug 2007 This compound is still undergoing active development